As CAR-Ts Proliferate, CMS Seeks To Reserve Medicare Add-On Payments For ‘New’ Therapies

 
• By Cathy Kelly

Products from Bristol-Myers Squibb, Gilead and J&J might be eligible for supplemental reimbursement under hospital payment proposed rule that could help promote uptake.

New Phase Of Medicare Reimbursement Policy For CAR-T Therapies • Source: Alamy

More from Cell & Gene Therapies

More from Advanced Technologies